Ovarian cancer drug trial halted early: niraparib vs chemo
NCT ID NCT06964165
First seen Dec 26, 2025 · Last updated May 24, 2026 · Updated 20 times
Summary
This study aimed to see if the drug niraparib works better than standard chemotherapy for people with advanced ovarian cancer that has a specific genetic feature (HRd). The trial was stopped early after enrolling 36 participants. Researchers planned to measure tumor shrinkage before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
San Francisco, California, 94115, United States
-
GSK Investigational Site
Miami, Florida, 33136, United States
-
GSK Investigational Site
Tampa, Florida, 33606, United States
-
GSK Investigational Site
Scarborough, Maine, 04074, United States
-
GSK Investigational Site
Boston, Massachusetts, 02114, United States
-
GSK Investigational Site
St Louis, Missouri, 63141, United States
-
GSK Investigational Site
New York, New York, 10029, United States
-
GSK Investigational Site
New York, New York, 77030, United States
-
GSK Investigational Site
Rochester, New York, 14642, United States
-
GSK Investigational Site
Sioux Falls, South Dakota, 57105, United States
-
GSK Investigational Site
Seattle, Washington, 98104, United States
-
GSK Investigational Site
Ottawa, Ontario, K1H 8L6, Canada
-
GSK Investigational Site
Montreal, Quebec, H2X 0A9, Canada
-
GSK Investigational Site
Montreal, Quebec, H4A 3J1, Canada
-
GSK Investigational Site
A Coruña, ES, 15006, Spain
-
GSK Investigational Site
Madrid, ES, 28027, Spain
-
GSK Investigational Site
Madrid, ES, 28033, Spain
-
GSK Investigational Site
Madrid, ES, 28050, Spain
-
GSK Investigational Site
Madrid, ES, 28223, Spain
-
GSK Investigational Site
Málaga, ES, 29001, Spain
-
GSK Investigational Site
Pamplona, ES, 31008, Spain
Conditions
Explore the condition pages connected to this study.